The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis
Article first published online: 5 MAY 2005
Volume 6, Issue 3, pages 191–197, May 2005
How to Cite
Winston, A., McAllister, J., Amin, J., Cooper, D. and Carr, A. (2005), The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis. HIV Medicine, 6: 191–197. doi: 10.1111/j.1468-1293.2005.00288.x
- Issue published online: 5 MAY 2005
- Article first published online: 5 MAY 2005
- Received: 9 August 2004, accepted 2 December 2004
- 3Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol 2000; 74: 5747–5753., , et al.
- 5Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72: 4265–4273., , et al.
- 11[Recommendations for non-occupational postexposure HIV prophylaxis. Spanish Working Group on Non-Occupational Postexposure HIV Prophylaxis of the Catalonian Center for Epidemiological Studies on AIDS and the AIDS Study Group]. Enferm Infecc Microbiol Clin 2002; 20: 391–400 (in Spanish)., , et al.
- 14CDC. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. Morb Mortal Wkly Rep Recomm Rep 2001; 50: 1–52.
- 26NCHECR. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia. Annual Surveillance Report 2003. Sydney, Australia, National Centre in HIV Epidemiology and Clinical Research, the University of New South Wales, 2003.
- 29Pharmacokinetics (PK) of stavudine (d4T) extended release formulation compared with stavudine immediate release (IR) formulation as part of potent antiretroviral combination therapy. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February, 2002, [Abstract 430]., , , , ,